AN2 Therapeutics
Developing therapies for rare, chronic, and serious infectious diseases
Developing therapies for rare, chronic, and serious infectious diseases
AN2 Therapeutics is a biopharmaceutical company founded in 2017 with a mission to develop therapies for rare, chronic, and serious infectious diseases in areas of high unmet needs. The company’s slogan, “Developing therapies for rare, chronic, and serious infectious diseases," underlines its commitment to addressing critical medical challenges. Headquartered in the United States, AN2 Therapeutics is focused on leveraging the expertise of its experienced leadership team in infectious disease drug research and boron chemistry to make a meaningful impact on global human health. The company received a grant investment on 26 September 2023 from the Bill & Melinda Gates Foundation, demonstrating recognition and support from prominent investors in the healthcare and philanthropic sectors. For more information, please visit www.an2therapeutics.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 |
|
26 Sep 2023 |
| Post-IPO Equity | $70.00M | 8 |
|
15 Aug 2023 |
| Series B | $80.00M | 1 | Avidity Partners | 07 Jan 2022 |
| Series A | $12.00M | - | 21 Nov 2019 |
No recent news or press coverage available for AN2 Therapeutics.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
